Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients
Status:
Withdrawn
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to demonstrate that a continuous infusion of intravenous
(IV) heparin (UFH) for Venous thromboembolism (VTE) prophylaxis will restore prophylactic
levels of heparin in high-risk critically ill medical patients as compared with guideline
recommended subcutaneous heparin. Antifactor Xa assay, a laboratory test to measure the
anticoagulant activity of heparin, or the ability of heparin to thin the blood, will be used
to demonstrate that Intravenous administration is more effective.
Phase:
N/A
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health